Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium (Nasdaq: COLL) announced management will participate in three investor conferences in Nov–Dec 2025.
Jefferies London Healthcare Conference presentation: Nov 19, 2025 at 8:00 a.m. GMT in London; webcast available via the Investors section and replay archived for 90 days.
Piper Sandler 37th Annual Healthcare Conference fireside chat: Dec 2, 2025 at 2:30 p.m. ET in New York; webcast available via the Investors section and replay archived for 90 days.
Evercore Healthcare Conference: Dec 4, 2025 in Coral Gables, FL; details and webcasts available from the Investors section.
Collegium (Nasdaq: COLL) reported record Q3 2025 net revenue of $209.4M, up 31% year‑over‑year, and raised full‑year 2025 net revenue guidance to $775–$785M. The company posted Q3 adjusted EBITDA of $133.0M (up 27% YoY) and raised adjusted EBITDA guidance to $460–$470M. Jornay PM net revenue was $41.8M in Q3 with prescriptions up 20% YoY and 27,700 prescribers (up 22% YoY). The pain portfolio generated a record $167.6M in Q3. Collegium ended the quarter with $285.9M in cash, cash equivalents and marketable securities and generated $78.4M in operating cash flow.
Collegium Pharmaceutical (Nasdaq: COLL) announced a collaboration with entrepreneur and advocate Paris Hilton to share her personal ADHD journey and treatment experience on Oct 29, 2025.
The campaign aims to reduce stigma and encourage patients to talk with healthcare providers about treatment options. The release notes ADHD prevalence estimates of 15.5 million adults and 6.5 million children in the U.S., with ~70% of cases persisting into adulthood. Paris Hilton described being diagnosed as a young adult and choosing treatment with JORNAY PM (methylphenidate HCl) ER, a nighttime-dosed stimulant that starts on waking and lasts through the day.
Collegium Pharmaceutical (Nasdaq: COLL) announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. The company will host a live conference call and webcast at 8:00 a.m. ET following the release.
Conference call dial-in numbers are (877) 407-8037 (U.S.) and (201) 689-8037 (International) referencing the “Collegium Pharmaceutical Q3 2025 Earnings Call.” An audio webcast and a replay will be available from the Investors section of the company website at www.collegiumpharma.com, with the replay posted about two hours after the event.
Collegium Pharmaceutical (Nasdaq: COLL) will present real-world data posters on its ADHD product Jornay PM at two fall conferences during ADHD Awareness Month.
At AACAP in Chicago (October 20-25, 2025) a poster titled "Determining the Optimal Dose of Methylphenidate HCl (JORNAY PM) in Adolescents and Adults" is scheduled for Oct 22, 4–6 p.m. CDT at Hyatt Regency. At NEI Fall Congress in Colorado Springs (Nov 6-9, 2025) a poster titled "JORNAY PM in Practice: Real-World Evidence Exploration of Utilization and Patient Response" is scheduled for Nov 7, 4–5 p.m. MST at Broadmoor West.
Important safety note: JORNAY PM is a Schedule II controlled stimulant with abuse, dependence, and cardiovascular and psychiatric risks; see prescribing information for details.
Collegium (Nasdaq: COLL) will ring the Nasdaq opening bell on October 14, 2025 at 9:30 a.m. ET to celebrate its 10-year anniversary as a publicly traded company.
The company highlighted its expansion into neuropsychiatry via the acquisition of Jornay PM for ADHD, noting Jornay PM is currently the fastest growing stimulant medicine for ADHD. Collegium said its financial strength, business development track record, and commercial expertise position it to continue serving patients and pursuing growth. A live stream of the Nasdaq opening bell will be available at the Nasdaq bell-ringing page.
Collegium Pharmaceutical (Nasdaq: COLL) has announced its participation in three upcoming investor conferences in September 2025. The company will attend the 2025 Wells Fargo Healthcare Conference on September 4 in Boston, participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 8 at 2:35 p.m. ET in New York, and present at the H.C. Wainwright Global Investment Conference on September 9 at 10:30 a.m. ET in New York.
Live webcasts of the fireside chats will be accessible through Collegium's investor relations website, with replays available for 90 days after the presentations.
Collegium Pharmaceutical (Nasdaq: COLL) will present nine posters featuring real-world data from its pain management portfolio at PAINWeek 2025 in Las Vegas from September 2-5, 2025. The presentations will focus on data from their key products BELBUCA® and XTAMPZA® ER.
The research includes studies on treatment characteristics, safety profiles, economic burden, and clinical outcomes for chronic low back pain patients. Chief Medical Officer Thomas Smith emphasized that these findings will provide healthcare professionals with valuable insights to support clinical decision-making. The poster session is scheduled for September 4, 2025, from 4:00 to 5:30 PM PT.
Collegium Pharmaceutical (Nasdaq: COLL) reported strong Q2 2025 financial results, achieving record quarterly revenue of $188.0 million, up 29% year-over-year. The company's ADHD medication Jornay PM generated record revenue of $32.6 million with 23% prescription growth, while the pain portfolio contributed $155.4 million, up 7% year-over-year.
The company raised its 2025 guidance, now expecting full-year revenue between $745-760 million and adjusted EBITDA of $440-455 million. Q2 highlights include adjusted EBITDA of $105.1 million and cash position of $222.2 million. The Board authorized a new $150 million share repurchase program through 2026, following completion of a $25 million accelerated share repurchase.
Collegium Pharmaceutical (Nasdaq: COLL) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, before market opening. The company will host a conference call and webcast at 8:00 a.m. ET following the release.
Investors can access the conference call via (877) 407-8037 (U.S.) or (201) 689-8037 (International). An audio webcast will be available on the company's website investor section and will remain accessible for replay approximately two hours after the event.